FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2894795030> ?p ?o ?g. }

• W2894795030 endingPage "1950" @default.
• W2894795030 startingPage "1943" @default.
• W2894795030 abstract "One of the most important long-term side effects of therapy for rheumatoid arthritis (RA) is the elevation of liver function tests, with earlier studies reporting an elevation of more than 1× the upper limit of normal (>1 × ULN). The current study expands the literature by comparing the trends of transaminase changes caused by conventional and biologic disease-modifying antirheumatic drugs (DMARDs).The drug categories examined were methotrexate (MTX) and all other nonbiologic DMARDs. Where RA patients exhibited inadequate response to conventional DMARDs (cDMARDs), we added biologic DMARDs (bDMARDs) to the treatment. We compared the trend of changes in alanine aminotransferase (ALT) and aspartate aminotransferase (AST) in the patients receiving MTX with the trend observed in the patients whose treatment encompassed both bDMARDs and MTX. The comparison was conducted using random intercept models, which are a type of linear mixed effects model.This work involved 512 RA patients (MTX: 450, MTX + infliximab [INF]: 26, MTX + etanercept [ETA]: 36), whose ALT and/or AST levels were measured in 1,786 visits (MTX: 1,543, MTX + INF: 107, MTX + ETA: 136). ALT and/or AST elevations greater than 1 × ULN were observed in 344 (19.3%) visits (MTX: 295 [19.1%], MTX + INF/ETA: 49 [20.2%]). In this study, the trends of ALT and AST changes increased when receiving MTX, while the INF/ETA addition decreased these trends. The random intercept models indicated that changes in the mean ALT levels were significantly different over the time for MTX and MTX + INF/ETA groups (β [SE] =-0.190 [0.093], P= 0.040) but changes in the mean AST levels were nonsignificantly different over the time for such groups (β [SE] =-0.099 [0.064], P=0.120).Despite a higher incidence of elevated transaminases during the use of MTX + INF/ETA, the combination of INF/ETA with MTX reduced transaminase levels and returned ALT levels to normal concentrations." @default.
• W2894795030 created "2018-10-12" @default.
• W2894795030 creator A5023809920 @default.
• W2894795030 creator A5027722795 @default.
• W2894795030 creator A5039260981 @default.
• W2894795030 creator A5057017762 @default.
• W2894795030 creator A5072320458 @default.
• W2894795030 creator A5072930471 @default.
• W2894795030 creator A5077354751 @default.
• W2894795030 date "2018-10-01" @default.
• W2894795030 modified "2023-10-13" @default.
• W2894795030 title "Additional effect of etanercept or infliximab on the liver function tests of patients with rheumatoid arthritis: a cohort study" @default.
• W2894795030 cites W19112365 @default.
• W2894795030 cites W1973564016 @default.
• W2894795030 cites W1989353729 @default.
• W2894795030 cites W1991380726 @default.
• W2894795030 cites W1997282832 @default.
• W2894795030 cites W2028132386 @default.
• W2894795030 cites W2057513792 @default.
• W2894795030 cites W2073578075 @default.
• W2894795030 cites W2076649628 @default.
• W2894795030 cites W2088209117 @default.
• W2894795030 cites W2089203162 @default.
• W2894795030 cites W2095595855 @default.
• W2894795030 cites W2110089395 @default.
• W2894795030 cites W2111153776 @default.
• W2894795030 cites W2120143305 @default.
• W2894795030 cites W2120393706 @default.
• W2894795030 cites W2133103918 @default.
• W2894795030 cites W2142399236 @default.
• W2894795030 cites W2147335241 @default.
• W2894795030 cites W2148193493 @default.
• W2894795030 cites W2154319559 @default.
• W2894795030 cites W2159025983 @default.
• W2894795030 cites W2160877509 @default.
• W2894795030 cites W2169279953 @default.
• W2894795030 cites W2766207844 @default.
• W2894795030 cites W4210768724 @default.
• W2894795030 cites W93019391 @default.
• W2894795030 doi "https://doi.org/10.2147/tcrm.s172836" @default.
• W2894795030 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6186305" @default.
• W2894795030 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30349273" @default.
• W2894795030 hasPublicationYear "2018" @default.
• W2894795030 type Work @default.
• W2894795030 sameAs 2894795030 @default.
• W2894795030 citedByCount "3" @default.
• W2894795030 countsByYear W28947950302019 @default.
• W2894795030 countsByYear W28947950302022 @default.
• W2894795030 countsByYear W28947950302023 @default.
• W2894795030 crossrefType "journal-article" @default.
• W2894795030 hasAuthorship W2894795030A5023809920 @default.
• W2894795030 hasAuthorship W2894795030A5027722795 @default.
• W2894795030 hasAuthorship W2894795030A5039260981 @default.
• W2894795030 hasAuthorship W2894795030A5057017762 @default.
• W2894795030 hasAuthorship W2894795030A5072320458 @default.
• W2894795030 hasAuthorship W2894795030A5072930471 @default.
• W2894795030 hasAuthorship W2894795030A5077354751 @default.
• W2894795030 hasBestOaLocation W28947950301 @default.
• W2894795030 hasConcept C126322002 @default.
• W2894795030 hasConcept C160160445 @default.
• W2894795030 hasConcept C17991360 @default.
• W2894795030 hasConcept C181199279 @default.
• W2894795030 hasConcept C185592680 @default.
• W2894795030 hasConcept C198451711 @default.
• W2894795030 hasConcept C2777138892 @default.
• W2894795030 hasConcept C2777226972 @default.
• W2894795030 hasConcept C2777575956 @default.
• W2894795030 hasConcept C2778606649 @default.
• W2894795030 hasConcept C2779679107 @default.
• W2894795030 hasConcept C2780132546 @default.
• W2894795030 hasConcept C2781059491 @default.
• W2894795030 hasConcept C2992208098 @default.
• W2894795030 hasConcept C55493867 @default.
• W2894795030 hasConcept C71924100 @default.
• W2894795030 hasConcept C90924648 @default.
• W2894795030 hasConceptScore W2894795030C126322002 @default.
• W2894795030 hasConceptScore W2894795030C160160445 @default.
• W2894795030 hasConceptScore W2894795030C17991360 @default.
• W2894795030 hasConceptScore W2894795030C181199279 @default.
• W2894795030 hasConceptScore W2894795030C185592680 @default.
• W2894795030 hasConceptScore W2894795030C198451711 @default.
• W2894795030 hasConceptScore W2894795030C2777138892 @default.
• W2894795030 hasConceptScore W2894795030C2777226972 @default.
• W2894795030 hasConceptScore W2894795030C2777575956 @default.
• W2894795030 hasConceptScore W2894795030C2778606649 @default.
• W2894795030 hasConceptScore W2894795030C2779679107 @default.
• W2894795030 hasConceptScore W2894795030C2780132546 @default.
• W2894795030 hasConceptScore W2894795030C2781059491 @default.
• W2894795030 hasConceptScore W2894795030C2992208098 @default.
• W2894795030 hasConceptScore W2894795030C55493867 @default.
• W2894795030 hasConceptScore W2894795030C71924100 @default.
• W2894795030 hasConceptScore W2894795030C90924648 @default.
• W2894795030 hasLocation W28947950301 @default.
• W2894795030 hasLocation W28947950302 @default.
• W2894795030 hasLocation W28947950303 @default.
• W2894795030 hasLocation W28947950304 @default.
• W2894795030 hasOpenAccess W2894795030 @default.
• W2894795030 hasPrimaryLocation W28947950301 @default.

• next